ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

NET formation in patients with COVID-19 and non-COVID-19 ARDS on venovenous ECMO

N. Buchtele1, M. Kollars2, H. Burgmann3, P. Kyrle2, T. Staudinger4, S. Eichinger5, L. Traby6

1Department of Medicine I,Intensivecare Unit 13i2, Medical University of Vienna, Vienna, Austria, Vienna, Wien, Austria, 2Department of Medicine I, Clinical Division of Hematology and Hemostasis, Medical University of Vienna, Vienna, Austria, Vienna, Wien, Austria, 3Department of Medicine I, Clinical Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria, Vienna, Wien, Austria, 4Department of Medicine I, Intensivecare Unit 13i2, Medical University of Vienna, Vienna, Austria, Vienna, Wien, Austria, 5 Medical University of Vienna, Vienna, Austria, Vienna, Wien, Austria, 6Medical University of Vienna, Vienna, Austria, Vienna, Wien, Austria

Abstract Number: PB0053

Meeting: ISTH 2022 Congress

Theme: COVID and Coagulation » COVID and Coagulation, Clinical

Background: Venovenous extracorporeal membrane oxygenation (ECMO) is a cornerstone in the management of severe acute respiratory distress syndrome (ARDS) and causes hemostatic system activation and inflammation. COVID-19 is known to cause thromboinflammation. Elucidation of the underlying pathomechanisms is of great importance.

Aims: To evaluate markers of NET formation in COVID-19 and non-COVID-19 associated ARDS and ECMO and to explore the role of different NET parameters as markers of inflammation and coagulopathy.

Methods: We studied 31 adult COVID-19 patients and 23 adult non-COVID-19 patients with severe ARDS requiring ECMO and 47 sex-and age-matched healthy controls. Blood was collected at time point A (ECMO day 0-4) and at time point B (ECMO day 7-17).

Citrullinated histone H3 (citH3), cell-free DNA (cfDNA), and plasma myeloperoxidase DNA (mpoDNA), as well as d-Dimer, were evaluated.

Values are given as median (25th, 75th percentile). Statistical testing was performed using unpaired t-tests of logarithmized parameters.

Results: COVID-19 and non-COVID-19 patients exhibited significantly higher levels of citH3, cfDNA, and mpoDNA than healthy controls (Table 1). Levels of citH3 decreased significantly from time point A to B in COVID-19 patients. No comparable effect was identified for cfDNA and mpoDNA (Table 1). In non-COVID-19 patients, no differences in levels of citH3, cfDNA, and mpoDNA were found between timepoints A and B (Table 1).

d-Dimer increased from time point A to timepoint B in both groups (Table 1).

Conclusion(s): NET formation is comparably increased in patients on ECMO because of COVID-19 and non-COVID-19 ARDS. Markers of NET formation could add information on immunothrombosis and the complex interplay of coagulation and inflammation in the context of ECMO.

Figure 1

Levels of citrullinated histone H3, cell-free DNA, myeloperoxidase DNA, and d-Dimer in COVID-19 and non-COVID-19 ECMO patients and in healthy controls

Table 1

Levels of citrullinated histone H3, cell-free DNA, myeloperoxidase DNA, and d-Dimer in COVID-19 and non-COVID-19 ECMO patients and in healthy controls

To cite this abstract in AMA style:

Buchtele N, Kollars M, Burgmann H, Kyrle P, Staudinger T, Eichinger S, Traby L. NET formation in patients with COVID-19 and non-COVID-19 ARDS on venovenous ECMO [abstract]. https://abstracts.isth.org/abstract/net-formation-in-patients-with-covid-19-and-non-covid-19-ards-on-venovenous-ecmo/. Accessed September 24, 2023.

« Back to ISTH 2022 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/net-formation-in-patients-with-covid-19-and-non-covid-19-ards-on-venovenous-ecmo/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress ยป

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 John Wiley & Sons, Inc. All Rights Reserved.
Wiley